Terms of Use   |   Privacy Statement
	© 2008 Amgen Inc. All Rights Reserved.  Prescribing Information   This site is intended for a US audience only. Sensipar® is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. Sensipar® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. Important Safety Information Sensipar® lowers serum calcium; therefore, it is important that patients have a serum calcium ≥ 8.4 mg/dL when initiating therapy. Significant reductions in calcium may lower the threshold for seizures. Secondary HPT patients, particularly those with a history of seizure disorder, should be carefully monitored for the occurrence of low serum calcium or symptoms of hypocalcemia. In Sensipar® postmarketing use, isolated, idiosyncratic cases of hypotension and/or worsening heart failure were reported in patients with impaired cardiac function. The causal relationship to Sensipar® therapy could not be completely excluded and may be mediated by reductions in serum calcium levels. The most commonly reported side effects were nausea, vomiting, and diarrhea.